---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-016947"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:09:05.328676+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# RenovoRx Q1 2023 net loss $3.3M; Phase III data shows 60% survival benefit

## Summary
- Cash and equivalents were $3.7M at March 31, 2023; net loss $3.3M vs $3.0M in Q1 2022.
- Phase III TIGeR-PaC interim analysis: 60% survival benefit, >65% reduction in side effects vs systemic chemo.
- Closed $5M registered direct offering subsequent to quarter end.
- Appointed Robert J. Spiegel (former CMO of Schering-Plough) to Board; Leesa Gentry as SVP Clinical Operations.
- Issued 8th U.S. patent extending RenovoTAMP therapy platform IP coverage.

## SEC filing metadata
- accession: 0001493152-23-016947
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315223016947/0001493152-23-016947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315223016947/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-016947
- JSON: https://secwatch.observer/filing/0001493152-23-016947.json
- Plain text: https://secwatch.observer/filing/0001493152-23-016947.txt

## Key facts
- Earnings Releases
  RenovoRx, Inc. reported the first quarter ended March 31, 2023 results: net income $3.3 million.
  - Period: the first quarter ended March 31, 2023
  - Net income: $3.3 million
  - Result: reported results
  source text: RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1574094/000149315223016947/0001493152-23-016947-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.